Home
Designing First-In-Human Trials for Small Molecules and Biologics
U.S. Food and Drug Administration
Apr 15, 2021
10,584 views
Getting to First-in-Human for Small Molecules and Biologics
FDA’s Clinical Regulatory Perspective: Designing First-In-Human Trial for Cellular and Gene Therapy
Modeling and Simulation to Select Oncology Dosages - Session 1
Bench to Bedside Chat Pharmacology and Dose Optimization for First-in-Human Oncology Trials
CMC Considerations for CAR T Cell Product Development
REdI Annual Conference 2024: CBER (Biologics) Innovation in Medical Product Development (Day 1 of 2)
Overview of the Guidance for Industry: Control of Nitrosamine Impurities in Human Drugs
Chemistry, Manufacturing Controls (CMC) in an Investigational New Drug (IND) (7/14) REdI 2017
Regulatory Education for Industry (REdI) Annual Conference 2024: Day 1 – Session 2
Regulatory Education for Industry (REdI) Annual Conference 2024: Day 2 – Session 2
Advancing the Use of Complex Innovative Designs in Clinical Trials: From Pilot to Practice - Part 1
Regulatory Education for Industry (REdI) Annual Conference 2024: Day 1 - Keynote and Plenary
FDA Omics Days 2024: Public afternoon sessions
Electronic Common Technical Document (eCTD)
Overview of Non-clinical Assessment in Drug Development (8/14) REdI 2017
Regulatory Education for Industry (REdI) Annual Conference 2024: Day 1 – Session 3
Regulatory Education for Industry (REdI) Annual Conference 2024: Day 2 – Session 1
Electronic Common Technical Document (eCTD) and Study Data (7of15) RedI – May 29-30, 2019
Regulatory Education for Industry (REdI) Annual Conference 2024: Day 1 – Session 1
FDA Omics Days 2024: Public morning sessions